Arpida announces positive in vitro results on AR-709
Results highlight the potential of AR-709 for the treatment of upper and lower Respiratory Tract Infections (RTIs)
Arpida Ltd announced positive results from in vitro microbiological studies conducted with AR-709, a broad-spectrum, bactericidal antibiotic that Arpida is developing for the treatment of upper and lower respiratory tract infections contracted in the community setting.
The studies, which were conducted by Prof. Michael R Jacobs at the University Hospitals of Cleveland, Ohio, aimed to determine the activity of AR-709 against a panel of 160 Streptococcus pneumoniae clinical isolates collected in the USA and Asia. All of the isolates had been previously phenotypically and genotypically characterized to determine their resistance profile to major antibiotic classes currently in use such as penicillins, cotrimoxazole and macrolides. The panel included 31% penicillin-intermediate, 37% penicillin-resistant, 62% cotrimoxazole-resistant and 57% macrolide-resistant clinical isolates. This last group harbored, among others, the mef gene responsible for conferring resistance to macrolides or the erm gene responsible for conferring resistance to macrolides, lincosamides and streptogramin B in 52% and 44% of the strains, respectively. Encouragingly, AR-709 exhibited potent activity against all of the isolates tested irrespective of the type and pattern of resistance.
Weitere News aus dem Ressort Forschung & Entwicklung
